Logo close icon
Studying with us during coronavirus in 2021

Allied Health Professions, Dentistry, Nursing and Pharmacy

Overview of Allied Health Professions, Dentistry, Nursing and Pharmacy

This submission presented work carried out in the biomedical science area within the School of Science and Technology at Middlesex University. Back in 2008, the Research Assessment Exercise placed our biomedical science research in the top half of Unit of Assessment, giving the university confidence and the impetus to develop and grow.

REF 2014 results highlights

  • 98% of Allied Health Professions, Dentistry, Nursing and Pharmacy research at Middlesex ranked as international recognised (2 star) or above, of which 67% was internationally excellent (3 star) and world-leading (4 star). 
  • Ranked above Brunel in GPA rankings and Greenwich and Roehampton in power rankings.

The increase in researchers at a level suitable for REF submission, interdisciplinary working with the strong bioinformatics team in computer science, our excellent infrastructure and a strong emphasis on developing new researchers have moved us into a position to build upon these foundations into a world-class research unit.

A total of 16 members of staff are involved, working in three research groups focused on the following areas: biophysics and bioengineering; biomarkers; and molecular biology. 

The individual Unit of Assessment case studies are:

This research project resulted in the contribution of several public domain, open-source resources to the international industrial and commercial research communities, such as novel reconstruction algorithms, geometric models for generating accurate finite element and boundary element forward models and methods to generate subject-specific forward models. It has also resulted in two patents.

Download this case study as a PDF.

Development of an anti-hCGβ cancer vaccine for the treatment of bladder cancer and other hCG/hCGβ secreting tumours

Summary: Our research has underpinned the work of Celldex Therapeutics and other US-based companies in developing a vaccine directed against hCGβ for the adjuvant treatment of epithelial cancer. A number of Phase I trials indicated an improvement in survival of vaccinated patients, and Phase II trials began for bladder cancer where early data showed promise by improving the survival time. This has had a significant impact on these patients and has the potential to extend the life of many millions of cancer sufferers (around 32 per cent frequency of hCGβ secretion by carcinomas). Our research input has helped prove the technology and further trials are awaiting finance.

Download this case study as a PDF.

In this section

Back to top